LEADER 02889nam 2200409 450 001 9910569198203321 005 20230608020114.0 035 $a(CKB)4100000012155979 035 $a(NjHacI)994100000012155979 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81838.2 035 $a(EXLCZ)994100000012155979 100 $a20221105d2021 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aProstate cancer /$fedited by Simon Bott, Keng Lim Ng 210 $aAustralia$cExon Publications$d2021 210 1$aBrisbane, AU :$cExon Publications,$d[2021] 210 4$dİ2021 215 $a1 online resource (xiv, 157 pages) $cillustrations 311 $a0-645-00175-9 320 $aIncludes bibliographical references. 330 $aProstate cancer is a life-altering diagnosis, not just for patients, but for their loved ones as well. Once, prostate cancer was most frequently diagnosed in men in their 60s and 70s; with increasing use of imaging modalities and PSA testing, the incidence is on the rise, and we are now seeing men in their 40s with the disease. This poses a challenge for clinical management depending on the stage of the disease?from watchful waiting or active surveillance to aggressive treatment with the risk of therapeutic nihilism. Despite being one of the most common cancers in Western men, its natural history, prognosis, and treatment are poorly understood. This book brings together a select faculty of experts to present a comprehensive view of the current state and future perspectives of prostate cancer. There are ten chapters in the book?the first four cover our present knowledge and understanding of the disease, the following three explore new advancements and treatments, particularly looking at overcoming resistance to therapy, and the remaining three chapters focus on specific molecules with the potential to become drug targets. We all have much to learn about prostate cancer. This book is aimed primarily at clinicians and scientists, but many areas will also be of interest to the layperson. 606 $aProstate$xCancer 610 $aEpidemiology of Prostate Cancer; Etiology of Prostate Cancer; Pathogenesis of Prostate Cancer; Current Diagnostics for Prostate Cancer; Combination Treatment for Prostate Cancer; Castration-Resistant Prostate Cancer; Theranostics in Metastatic Castrate Resistant Prostate Cancer; Adenocarcinoma of the Prostate; p53 in Prostate Cancer; MUCIN 1 in Prostate Cancer; STEAP Proteins in Prostate Cancer 615 0$aProstate$xCancer. 676 $a616.99463 702 $aBott$b Simon 702 $aNg$b Keng Lim 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910569198203321 996 $aProstate Cancer$91754837 997 $aUNINA